厄达替尼
Tier C — Watch / tradeErdafitinib · all drugs expiring in 2030 →
Targets：FGFR4、FGFR1、FGFR3、FGFR2
Brand：博珂、Balversa
Indications (approved)：尿路上皮癌、泌尿系肿瘤
Regional status
Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ERDA-001 | 50998-17-9 | 6-bromoquinoxaline |
| ERDA-002 | 761446-44-0Available | 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole |
| ERDA-003 | 1346245-03-1 | 2-(1-methyl-1H-pyrazol-4-yl)-7-nitroquinoxaline |
| ERDA-004 | 1083325-87-4 | 7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline |
| ERDA-005 | 10272-07-8 | 3,5-dimethoxyaniline |
| ERDA-006 | 1346133-39-8 | N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine |
| ERDA-007 | 86864-60-0 | (2-bromoethoxy)(tert-butyl)dimethylsilane |
| ERDA-008 | 1346245-08-6 | N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine |
| ERDA-009 | 1346242-78-1 | 2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethanol |
| ERDA-010 | 1346245-10-0 | 2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethyl methanesulfonate |
| Erdafitinib | 1346242-81-6 | - |
| Code | CAS No. | Intermediate |
|---|---|---|
| ERDA-003 | 1346245-03-1 | 2-(1-methyl-1H-pyrazol-4-yl)-7-nitroquinoxaline |
| ERDA-011 | 55686-94-7 | 2-chloro-7-nitroquinoxaline |
| ERDA-012 | 1346245-03-1 | - |
| ERDA-013 | 1346245-04-2 | 3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine |
| ERDA-014 | 20469-65-2 | 1-bromo-3,5-dimethoxybenzene |
| ERDA-015 | 1346133-39-8 | N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine |
| ERDA-016 | 6306-61-2 | N-(2-chloroethyl)propan-2-amine hydrochloride |
| Erdafitinib | 1346242-81-6 | - |
| Code | CAS No. | Intermediate |
|---|---|---|
| ERDA-009 | 1346242-78-1 | 2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethanol |
| ERDA-010 | 1346245-10-0 | 2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethyl methanesulfonate |
| ERDA-017 | 627-11-2 | 2-chloroethyl carbonochloridate |
| ERDA-018 | 1021002-43-6 | 2-((3,5-dimethoxyphenyl)amino)ethanol |
| ERDA-019 | 1346245-09-7 | N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3,5-dimethoxyaniline |
| Erdafitinib | 1346242-81-6 | - |
| ERDA-004 | 1083325-87-4 | 7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline |
| ERDA-005 | 10272-07-8 | 3,5-dimethoxyaniline |
| ERDA-008 | 1346245-08-6 | N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine |
Frequently asked questions
What are the approved indications of Erdafitinib?
Approved indications include: 尿路上皮癌, 泌尿系肿瘤.
When does the Erdafitinib patent expire?
Based on public sources, the Erdafitinib patent expires in 2030.
How many synthesis routes are recorded for Erdafitinib?
3 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Erdafitinib intermediates?
1 intermediate CAS of Erdafitinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Erdafitinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24